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Abstract
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. Through
examination of 194 human prostate tumors, we observed statistically significant co-occurrence of MYC amplification and
PI3K-pathway alteration, raising the possibility that these two lesions cooperate in prostate cancer progression. To
investigate this, we generated bigenic mice in which both activated human AKT1 and human MYC are expressed in the
prostate (MPAKT/Hi-MYC model). In contrast to mice expressing AKT1 alone (MPAKT model) or MYC alone (Hi-MYC model),
the bigenic phenotype demonstrates accelerated progression of mouse prostate intraepithelial neoplasia (mPIN) to
microinvasive disease with disruption of basement membrane, significant stromal remodeling and infiltration of
macrophages, B- and T-lymphocytes, similar to inflammation observed in human prostate tumors. In contrast to the
reversibility of mPIN lesions in young MPAKT mice after treatment with mTOR inhibitors, Hi-MYC and bigenic MPAKT/Hi-
MYC mice were resistant. Additionally, older MPAKT mice showed reduced sensitivity to mTOR inhibition, suggesting that
additional genetic events may dampen mTOR dependence. Since increased MYC expression is an early feature of many
human prostate cancers, these data have implications for treatment of human prostate cancers with PI3K-pathway
alterations using mTOR inhibitors.
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Introduction
Prostate cancer is the secondmost common cause of cancer-related
deaths in American men, who carry a 16% lifetime risk of developing
invasive prostate cancer. Effective treatment of early-stage localized
disease involves active surveillance, surgery (radical prostatectomy) or
radiation therapy; however, recurrent and/or metastatic disease is
incurable and androgen deprivation therapy is the primary treatment
modality [1,2]. The predominant genetic and cellular changes in
human prostate cancer include presence of the TMPRSS2-ERG gene
fusion [3]; loss of the phosphatase and tensin homolog (PTEN) tumor
suppressor gene leading to accumulation of its substrate phosphati-
dylinositol 3,4,5-triphosphate (PIP3) and constitutive PI3K-pathway
up-regulation [4]; amplification, over-expression or mutation of the
androgen receptor (AR) [2]; and amplification of theMYC oncogene
[5,6]. Activating mutations in some signaling pathways can lead to
tumor cell ‘addiction’ to that same pathway, providing an Achilles
heel for clinical intervention.
The PI3K-pathway activates multiple targets including AKT and
its downstream effector mammalian target of rapamycin (mTOR)
[7,8], thus promoting cell growth and survival by suppression of
apoptosis and modulation of glucose uptake and cellular metabo-
lism [9]. mTOR function is governed by its participation in the
mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2)
multiprotein complexes [7,8]. AKT is one of several mTORC2
kinase substrates, whereas activated mTORC1 phosphorylates two
key effectors: i) eukaryotic initiation factor 4E–binding protein 1
(4EBP1) that regulates cap-dependent protein translation; and ii)
ribosomal protein S6 kinase 1 (S6K1) that in turn phosphorylates
40S ribosomal protein S6, leading to protein synthesis.
PI3K-pathway inhibitors are undergoing clinical evaluation in
multiple tumor types [10] including prostate cancer [11]. Despite
promising preclinical efficacy in PI3K-pathway-dependent pros-
tate cancer models [12,13,14], there have been only sporadic
clinical responses in single-agent trials with rapamycin analogs
(rapalogs, eg CCI-779, RAD001) targeting the PI3K-pathway via
allosteric inhibition of mTORC1 [15,16]. One reason for the
limited clinical efficacy of mTOR inhibitors could be a
compensatory upregulation of PI3K signaling to mitigate the
inhibitory block placed on the rapamycin-sensitive mTORC1
complex, either via release of the negative feedback on AKT that is
potentiated by activated S6K in the absence of rapamycin, or via
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mTORC2 signaling, which is largely insensitive to rapamycin
[17,18,19]. Additionally, mTORC1 inhibition can lead to
feedback activation of mitogen-activated protein kinase (MAPK)
signaling via an S6K-PI3K-Ras-dependent pathway [20]. Further-
more, rapamycin does not fully inhibit mTORC1, as demonstrat-
ed by comparison with ATP-competitive mTOR kinase inhibitors
[16]. Another explanation for rapalog failure in the clinic is that
tumorigenesis depends on accumulation of more than one genetic
aberration in pathways regulating cell proliferation and survival
[21]. Elucidation of these cooperating lesions is essential to
development of effective therapeutic strategies.
The MYC transcription factor directly regulates expression of
the translational machinery for protein synthesis, as well as genes
controlling cell cycle progression, metabolism, mitochondrial
number and function and stem cell self renewal [22]. A potential
cooperative role for PI3K-pathway activation and the MYC
oncogene has not yet been documented in human prostate cancer,
although pathway-interaction has been suggested by several in vitro
and in vivo models [23,24,25].
We identified an association between PI3K-pathway alteration
and MYC amplification in a cohort of primary and metastatic
human prostate cancer samples. To explore a cooperative role for
the PI3K-pathway with the MYC oncogene in human prostate
cancer, we used existing murine models of human prostate cancer
harboring prostate-specific homozygous deletion of PTEN
(PTENpc2/2 model) [26,27], or over-expression of either human
MYC (Hi-MYC model) [28] or the downstream PI3K-pathway
active allele of AKT1 (MPAKT model) [29] and studied the
combinatorial effect of these pathways on tumorigenesis. Initial
generation of a PTENpc2/2/Hi-MYC bigenic cross was used to
validate results of a related study [24] that demonstrated an
interaction between PTEN and MYC signaling using prostate-
specific deletion of PTEN with concurrent Cre-induced focal MYC
expression to induce high-grade mPIN (HG-mPIN) lesions and
invasive adenocarcinoma. To address whether AKT downstream
of PTEN might be the key mediator, we further explored the
cooperation between these pathways using a bigenic mouse cross,
MPAKT/Hi-MYC. Treatment with an mTOR inhibitor allowed
direct assessment of the impact of MYC expression on the well-
documented sensitivity of prostate lesions in the activated AKT
model [14]. Our results suggest the disappointing clinical activity
of single-agent rapamycin analogs in PTEN-deficient human
cancers, as compared to single-lesion transgenic mouse models,
may arise from secondary genetic alterations in human tumors.
Materials and Methods
Detailed methods are provided as supplemental information
(Text S1).
Ethics statement
Human prostate tissues analyzed in this study were from patients
treated atMemorial Sloan-Kettering Cancer Center (MSKCC), all of
whom provided written informed consent. The study was approved
by the MSKCC Institutional Review Board and the MSKCC
Human Tissue Utilization Committee. Animal studies were carried
out under protocol 06-07-012 approved by the MSKCC Institutional
Animal Care and Use Committee. Institutional guidelines for the
proper, humane use of animals in research were followed.
Comparative Genomic Hybridization Analysis of human
tumors
Copy number data from 194 high-quality primary and
metastatic tumors were generated using the Agilent 244K aCGH
array, and tumors assessed for genomic gain or amplification in
MYC, PIK3CA, AKT1, AKT2 and AKT3, and for PTEN-loss (Table
S1). The complete aCGH dataset is reported separately [30] and
available online at http://cbio.mskcc.org/prostate-portal/.
Generation, treatment and characterization of
PTENpc2/2/Hi-MYC and MPAKT/Hi-MYC mice
PTENpc2/2 mice (PtenloxP/loxP/Pb-Cre4) have been described
[26,27]. Hi-MYC mice (ARR2PB-Flag-MYC-PAI transgene) [28]
were crossed with PTENloxP/loxP mice [26,27], and PTENloxP/loxP/
Hi-Myc offspring (F2) crossed with PTENloxP/wt/Pb-Cre4 males
[26,27,31] generating bigenic PTENpc2/2/Hi-MYC mice (F3).
MPAKT (rPb-myr-HA-AKT1 transgene) [29] and Hi-MYC mice
were cross-bred to generate MPAKT/Hi-MYC mice. Males in
treatment cohorts were dosed qd with either 10 mg/kg (po) RAD001
emulsion or placebo (Novartis Pharma AG) for 14d, unless otherwise
noted. Tissues were stained for histologic or immunohistochemical
analysis; imaged slides are available online at http://cbio.mskcc.org/
Public/Sawyers_Clegg_AktMyc_2010. Gene and protein expression
were assessed by quantitative real-time RT-PCR and immunoblot.
Results
MYC amplification co-occurs with PI3K-pathway
activation in human prostate tumors
Activation of the PI3K signaling pathway, often via PTEN
inactivation, and amplification of MYC are common genetic
alterations in prostate cancer that correlate with high histological
grade and poor prognosis [5,32]. To evaluate whether PI3K-
pathway activation and MYC oncogene amplification co-occur in
human prostate cancer, we examined oligonucleotide array CGH
data from 194 prostate tumors, including 37 metastases. PI3K-
pathway activation rarely occurred through point mutation of
PTEN or PIK3CA in this dataset: exon-resequencing of 80 tumors
revealed only 2 tumors with PIK3CA mutation and none with
PTEN mutation [30].
PI3K-pathway activation, representing combinatorial alter-
ations in PTEN, PIK3CA, AKT1, AKT2 and AKT3 (single- or
multi-copy), was found in 27% of all samples and 70% of
metastases. MYC multi-copy gain was identified in 6% of all
samples and 24% of metastases, increasing to 20% of all samples
and 51% of metastases when both single- and/or multi-copy MYC
gain are considered (Table S1) [5,6,32]. We examined whether
tumors harboring PI3K-pathway alteration were enriched for
MYC copy-number gain (single-copy or greater) and found a
positive association (P= 0.0002, Fisher’s two-tailed exact test;
Figs. 1, S2A). Enrichment of PI3K-pathway copy-alterations and
high-level MYC amplification was also observed (P= 0.0004; Figs.
S1A, S2A). The subset of tumors with specific PIK3CA
amplification also showed an association with MYC amplification
(Figs. 1, S1A, S2A). There was also a statistically significant
association between PI3K-pathway alterations and MYC multi-
copy gain in metastases (P = 0.036, Figs. S1B–C, S2B). These data
establish that alterations in the PI3K-pathway are enriched with
MYC amplification in human prostate tumors.
MYC and AKT cooperate to accelerate progression of
mPIN to invasion in a murine prostate cancer model
To assess the functional implications of the association between
PI3K-pathway alteration andMYC amplification in human prostate
tumors, we turned to genetically engineered mouse (GEM) models.
The role of PI3K signaling in prostate cancer has been modeled in
mice by deletion of PTEN or by transgenic expression of activated
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AKT, while the role of MYC has been investigated by transgenic
expression of MYC. A recent study demonstrated interaction
between PTEN andMYC signaling using prostate-specific hetero- or
homozygous deletion of PTEN with concurrent focal probasin-Cre-
drivenMYC overexpression [24]. In order to validate this result in a
model with widespread prostate-specific MYC expression, and
provide rationale for more extensive studies of the role of AKT, we
employed the Hi-MYC [28] transgenic model (FVB background) in
a bigenic cross with the prostate-specific PTENpc2/2 conditional
knockout mouse (C57BL/6J strain) [26,27] to generate bigenic
PTENpc2/2/Hi-MYC mice.
In the Hi-MYC model [28], the modified (ARR2PB) probasin
promoter-driven expression of human MYC in the prostate results
in murine prostate intraepithelial neoplasia (mPIN) in the lateral
prostate (LP) by 4 weeks of age that progresses to adenocarcinoma
in all mice by 6–9 months. The ventral prostate (VP), dorsal
prostate (DP) and anterior prostate (AP) are affected to a lesser
extent. The PTENpc2/2 model expresses probasin-Cre4 (Pb-
Cre4) [31] upon puberty, thereby inactivating the floxed PTEN
alleles in the VP, LP, DP and AP. PTENpc2/2 mice develop HG-
mPIN that progresses to invasive adenocarcinoma after ,6
months of age [26,27].
PTENpc2/2/Hi-MYC bigenic mice have large prostatic adeno-
carcinomas at 3 months (Fig. 2), well in advance of either of the well-
established single lesion models, which at this stage harbor mPIN
exclusively (Fig. 2). Assessment of expression patterns for pAKT
(increased by inactivation of PTEN) and MYC in the PTENpc2/2/
Hi-MYC prostatic epithelium revealed a subpopulation of cells
expressing both proteins at high levels in areas of invasion (Fig. 2).
Consistent with previous work [24], PI3K-pathway activation and
MYC cooperate to accelerate progression of invasive prostate
cancer, providing the rationale to characterize this cooperation
more extensively and in a pure genetic background.
To address whether AKT, downstream of PTEN, might be
responsible for the interaction between PI3K-pathway activation
and MYC signaling, and whether mTOR is a key mediator, we
selected the established MPAKT [29] and Hi-MYC [28]
transgenic models, both in the FVB background strain, and
cross-bred them to generate MPAKT/Hi-MYC mice with
prostate-specific expression of both transgenes. In the MPAKT
model, over-expression of myristoylated human AKT1, driven by
a portion of the prostate-specific rat probasin promoter, leads to
phospho-AKT expression in luminal epithelial cells of predomi-
nantly the VP and rarely the LP. Expression of activated AKT
correlates with a highly-penetrant phenotype of mPIN in mice by
6–8-weeks-old [29].
Immunohistochemistry for phospho-AKT(Ser473) (pAKT) con-
firmed AKT activation in MPAKT and, at lower levels, in bigenic
MPAKT/Hi-MYC mice (Figs. 3B, S3A, S4). Similarly, immuno-
histochemical staining of MYC confirmed expression of the MYC
transgene in Hi-MYC and MPAKT/Hi-MYC mice (Figs. 3B,
S3A). Bigenic animals expressed lower levels of transgenic mRNA
than single transgenic mice (Fig. S3B). By 5–9 weeks, all three
strains (MPAKT, Hi-MYC and bigenic MPAKT/Hi-MYC mice)
had mPIN as expected (largely affecting VP in MPAKT mice, DP
and LP in Hi-MYC mice, but DP, LP and VP in bigenic mice)
(Fig. 3A). Although the growth pattern of mPIN lesions in Hi-
MYC and MPAKT/Hi-MYC mice were similar and often
cribriform, nuclear atypia was more pronounced in bigenic mice
(Fig. S5). At this early time-point, the key distinguishing feature in
MPAKT/Hi-MYC mice was significant stromal proliferation,
inflammation and remodeling in VP and LP with disruption of the
basement membrane and smooth muscle layer surrounding glands
affected by mPIN, and presence of epithelial cell clusters within
adjacent stroma (Figs. 3A, 4). This stromal remodeling phenotype
was further investigated by immunohistochemistry for smooth
muscle actin (SMA) and collagen IV, which revealed progressive
disruption and loss of the smooth muscle layer and basal laminae
in focal points around the proliferative glands suggesting early
microinvasion in ,70% of bigenic mice (Figs. 3C, 4, S6) [33]. In
summary, the histopathological features of mPIN lesions in the
bigenic mice were similar to those of Hi-MYC mice; however, the
stromal remodeling and inflammation, particularly severe in the
VP and LP, together with the nuclear atypia of proliferative cells
within areas of mPIN, were unique features of the bigenic mice
(Figs. 3, 4, S5, S6).
Progression to adenocarcinoma was accelerated in the
MPAKT/Hi-MYC model with evidence of invasion in 8% of
mice at 5–9 weeks, and in 67% mice at 16–20 weeks, compared
respectively with 0% and 25% of Hi-MYC mice (Figs. 3A, 3D, 4;
sample size precluded statistical significance). Of note is that
pAKT expression was occasionally evident in populations of cells
near the invasive regions (Fig. S4). In more advanced disease
beyond 6 months of age, the acceleration in disease progression
conferred by AKT activation in presence of MYC overexpression
was no longer evident (Fig. 4) (due to the highly penetrant MYC
alone phenotype), although the unique stromal reaction persisted
in the bigenic phenotype.
The MPAKT/Hi-MYC prostate lesions are accompanied by
infiltration of immune cells
The tumor microenvironment can significantly influence
tumorigenesis, and cells from the stromal compartment such as
fibroblasts and inflammatory cells can exert effects on adjacent
epithelial cells via paracrine signals and extracellular matrix
components [34]. To characterize the intense stromal remodeling
and inflammatory infiltrate surrounding mPIN and prostate
tumors in MPAKT/Hi-MYC mice, we performed immunohisto-
chemistry for T-lymphocytes (CD-3), B-lymphocytes (B220) and
macrophages (Mac-2) on prostate tissues from mice aged 5-9
weeks (Fig. 5). All three classes of immune cells were present at
high concentrations in the stromal infiltrate and in lesser amounts
within the epithelial compartment of mPIN lesions and tumors of
the MPAKT/Hi-MYC prostates. In contrast, only occasional
macrophages and T-cells were found surrounding mPIN lesions in
Hi-MYC prostates, and rare or no inflammatory cells were noted
in MPAKT or WT prostates. Thus, the unique stromal
remodeling and early invasive phenotype resulting from cooper-
ation between AKT1 and MYC in the mouse prostate is associated
Figure 1. MYC amplification co-occurs with AKT pathway
activation in human prostate tumor samples. Contingency tables
for co-occurrence of MYC and PI3K-pathway copy-number-alterations
(defined by aCGH) from 157 primary and 37 metastatic prostate tumor
samples. Indicated in red is the proportion of tumors (n = 194 total) with
PIK3CA amplification (left) or general PI3K-pathway gain (right) that also
exhibit single- or multi-copy MYC gain. Statistical significance for each
association is reported as a P-value (2-tailed Fisher’s exact test).
doi:10.1371/journal.pone.0017449.g001
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with an infiltration of T- and B-lymphocytes, as well as
macrophages.
AKT does not rescue MYC-induced apoptosis in the
prostate
To explore the cellular mechanism of AKT-MYC cooperativity,
we examined the prostates of bigenic mice and their littermates,
using markers of proliferation and apoptosis. As expected [28],
elevated levels of both proliferation (Ki67 staining) and apoptosis
(measured by TUNEL staining of DNA fragments) were seen in
Hi-MYC mPIN lesions (Fig. S7), consistent with the well-
established fact that MYC can induce both cell-proliferation and
apoptosis [22]. In contrast, Ki67 and TUNEL ratios were only
modestly elevated in MPAKT mice compared with WT (Fig. S7)
[14,29]. Ki67 staining in VP and LP of MPAKT/Hi-MYC was
comparable to Hi-MYC littermates, with highest proliferative rates
occurring in mPIN lesions. Previous reports using different model
systems and tissue-types have suggested PI3K-pathway activation
can rescue the proapoptotic phenotype of MYC overexpression
[35], providing a potential mechanism for cooperativity. However,
apoptotic rates remained high in mPIN lesions of MPAKT/Hi-
MYC mice and were not obviously different from Hi-MYC
littermates.
Transgenic MYC expression abrogates the mTOR-
dependence of the AKT-induced mPIN phenotype
The AKT-induced mPIN phenotype in young MPAKT mice is
dependent on mTOR [14]. We confirmed this in a cohort of 5-
week-old MPAKT mice treated with RAD001 or placebo (4-5
mice/treatment group) for 2 weeks (Fig. 6, left panels). As
expected, mPIN lesions in a cohort of 5-week-old Hi-MYC mice
did not revert after two weeks of RAD001 treatment and were
histologically indistinguishable from the lesions in control mice
(Fig. 6, center panels) confirming that mPIN in Hi-MYC mice
does not depend on mTOR signaling. We next examined the
mTOR dependence of mPIN lesions in bigenic MPAKT/Hi-
MYC mice by treatment of 5-week-old animals with either
RAD001 or placebo for 2 weeks. No reversion of the mPIN
phenotype upon RAD001 treatment was observed in the VP and
LP of the MPAKT/Hi-MYC mice, and the lesions were identical
to those of vehicle-treated mice (Fig. 6, right panels).
To confirm that mTOR was inhibited in RAD001-treated mice,
we examined the phosphorylation status of the downstream
mTOR substrate ribosomal-S6 protein by immunohistochemistry
with a widely-used phosphospecific antibody to Ser235/236 (pS6).
In all vehicle-treated MPAKT mice, pS6 in the regions of mPIN
was similarly high, and treatment with RAD001 led to
Figure 2. MYC cooperates with PI3K-pathway signaling in bigenic PTENpc2/2/Hi-MYC mice resulting in invasive adenocarcinoma
after 3 months. Mouse prostates (3–4 months), showing high-grade mPIN within glands of the PTENpc2/2 and Hi-MYC prostates, and
adenocarcinoma in the PTENpc2/2/Hi-MYC prostate. Upper panels: hematoxylin-and-eosin (H&E). Lower panels: Immunohistochemistry (IHC). Note
cellular expression of both pAKT and MYC in invasive areas of the PTENpc2/2/Hi-MYC prostate (dashed line), and basement membrane disruption
illustrated by loss of collagen IV staining. Scale-bars: 200 mm (black), 400 mM (red).
doi:10.1371/journal.pone.0017449.g002
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dramatically reduced pS6 staining (Fig. 6), indicating that
RAD001 effectively inhibited mTOR. pAKT expression was
retained, confirming continued transgene expression (Fig. 6). pS6
staining was also decreased by RAD001 treatment in MPAKT/
Hi-MYC and Hi-MYC mice, with some tissues showing residual
weak pS6 staining (Fig. 6). S235/236 of S6 is also the site for
phosphorylation by p90 ribosomal kinase (RSK), raising the
possibility of mTORC1-independent (therefore RAD001-resistant)
phosphorylation of S6 [36].
In summary, mPIN lesions in young MPAKT mice were fully
reverted upon RAD001-treatment; however, mPIN lesions in Hi-
MYC and MPAKT/Hi-MYC bigenic mice did not respond to
RAD001 despite effective mTORC1 inhibition. We conclude that
transgenic MYC expression is sufficient to override the mTOR
dependence of lesions arising from constitutive AKT activation.
RAD001 treatment did not affect intensity or composition of the
inflammatory infiltrate in prostates of bigenic mice.
The mTOR dependence of the activated AKT-driven mPIN
phenotype has been demonstrated only in youngMPAKTmice [14].
Having demonstrated that MYC can rescue the mTOR dependence
of AKT-driven mPIN lesions, we asked if the mPIN lesions of older
MPAKT mice would remain dependent on mTOR, or whether
additional genetic lesions potentially accumulated with aging might
render the prostate lesions insensitive to RAD001 treatment. In
contrast to youngMPAKTmice, the response of olderMPAKTmice
(28–32weeks-old) to mTOR inhibition was incomplete and variable
(Figs. 7, S8). Of seven mice treated with RAD001 for two weeks, five
had residual mPIN, whereas two had no evidence of mPIN. As
expected, mPIN was detected in the VP of all 6 placebo-treated mice.
pAKT was expressed in mPIN of vehicle-treated MPAKT mice and
in both RAD001-sensitive and RAD001-resistant mice, whereas loss
of pS6 staining in all RAD001-treated animals confirmed mTOR
inhibition (Fig. 7). Strong p27 expression, a documented marker of
mPIN in MPAKT mice [37], was observed in mPIN of the vehicle-
treated and RAD001-resistant MPAKT mice, but absent in WT
animals and in the reverted lesions of RAD001-sensitive mice,
providing additional evidence for RAD001-resistance (Fig. 7).
Therefore, the mPIN phenotype of MPAKT mice becomes
progressively independent of mTOR with age.
We next asked whether 4EBP1, an mTORC1 target, plays a
role in mediating the sensitivity to RAD001 in MPAKT mice, and
the RAD001-resistance in the Hi-MYC and MPAKT/Hi-MYC
models, as proposed by a study that used genetically engineered
prostate epithelial cells to examine the affect of MYC expression
on rapamycin sensitivity [23]. Surprisingly, immunohistochemical
assessment of 4EBP1 phosphorylation in the VP of mice aged 7-
weeks showed no decline in p4EBP1 levels in MPAKT mice
following 2 weeks of RAD001 treatment (Fig. 8), despite clear
histologic regression of mPIN lesions (Figs. 6, 8). Similarly,
expression of p4EBP1 in wild type, Hi-MYC and MPAKT/Hi-
MYC mice was either unchanged or slightly increased by RAD001
treatment (Fig. 8). We confirmed this result by immunoblot of
protein lysates from isolated ventral prostates, and verified the
increased 4EBP1 phosphorylation in the VP of RAD001-treated
mice, independent of total 4EBP1 expression (Fig. 8, S9).
Abrogation of pS6 expression along with increased glycogen
synthase kinase-3b (GSK3b) phosphorylation (a measure of AKT
activation due to relief of mTORC1-mediated feedback inhibition
of AKT) confirmed successful inhibition of mTOR (Figs. 8, S9).
Therefore 4EBP1 phosphorylation in WT, MPAKT, Hi-MYC
and MPAKT/Hi-MYC mice is not uniquely dependent on
mTOR and cannot explain resistance to mTOR inhibition.
MYC expression may confer resistance to rapamycin by
disrupting the balance between proliferation and apoptosis or
senescence. Interestingly, prostate tumors from Hi-MYC (n= 5)
and MPAKT/Hi-MYC (n= 5) mice all showed reduced TUNEL
staining after 14 days of RAD001 treatment compared to prostates
from vehicle-treated animals (n = 4–5/genotype) (Fig. 9, S10). The
Ki67 staining in the same tissues was unaffected by RAD001
treatment (Fig. 9, S10). Therefore, MYC expression does not
simply confer resistance to mTOR inhibition. The reduction in
apoptosis may, in fact, reveal paradoxical effects of mTOR
inhibitors on tumor progression.
Figure 4. MYC and AKT cooperate to accelerate progression to
microinvasion and adenocarcinoma in the MPAKT/Hi-MYC
model. Progression of a neoplastic phenotype (all prostate lobes) in
MPAKT, Hi-MYC and MPAKT/Hi-MYC, defined by presence of mPIN,
stromal remodeling typical of microinvasion, and development of
adenocarcinoma. Prostates assessed at 5–9 weeks (13–14 transgenics/
group), 16–20 weeks (4–6/group), and 6 months or greater (11–15/
group). Trend for progression to microinvasion and to adenocarcinoma,
respectively, was significant in Hi-MYC (p,0.0001, p =,0.0001) and
MPAKT/Hi-MYC (p = 0.02, p = 0.0002) (Cochran-Armitage trend test).
Significant differences (p,0.05, Fisher’s exact test) for microinvasion at
5–9 weeks: MPAKT/Hi-MYC vs Hi-MYC (p,0.001), MPAKT/Hi-MYC vs
MPAKT (p,0.001); microinvasion at 16–20 weeks: MPAKT/Hi-MYC vs
MPAKT (p = 0.002), Hi-MYC vs MPAKT (p = 0.03); microinvasion or
adenocarcinoma, respectively at .24 weeks: MPAKT/Hi-MYC vs MPAKT
(p =,0.0001, p =,0.0001), Hi-MYC vs MPAKT (p =,0.0001,
p =,0.0001). P = 0.06 for adenocarcinoma in MPAKT/Hi-MYC vs Hi-
MYC at 16–20 weeks.
doi:10.1371/journal.pone.0017449.g004
Figure 3. MYC cooperates with AKT in the MPAKT/Hi-MYC model resulting in extensive stromal remodeling typical of microinvasion
by 5–9 weeks. Mouse prostates at 7–9-weeks-old (A–C) or 15–16-weeks-old (D). (A) MPAKT has normal glands in lateral prostate (LP, lower panels)
and large areas of mPIN in ventral prostate (VP, upper panels); Hi-MYC and MPAKT/Hi-MYC have diffuse mPIN in VP (upper panels) and LP (lower
panels) (H&E). Scale-bars: 50 mm. (B) IHC indicating that AKT and MYC transgenes are expressed in prostates of bigenic MPAKT/Hi-MYC mice, albeit at
lower levels than in single lesion mice. High levels of pAKT membrane staining are associated with regions of mPIN in VP of MPAKT and are slightly
less intense and patchier in MPAKT/Hi-MYC, but absent in Hi-MYC. Nuclear MYC staining is evident in Hi-MYC and MPAKT/Hi-MYC VP, but absent in
MPAKT mice. Scale-bars: 50 mm. (C) IHC for SMA and collagen IV. Note disrupted and absent smooth muscle stroma and collagen IV in MPAKT/Hi-MYC
(right panels), compared to minimally attenuated smooth muscle sheath and collagen IV around areas of mPIN in Hi-MYC (center panels); smooth
muscle sheath remains intact in mPIN from MPAKT (left panels). Scale-bars: 100 mm. (D) Normal tissue (LP) and mPIN (VP) in MPAKT; diffuse mPIN in VP
and LP of Hi-MYC and MPAKT/Hi-MYC; frank adenocarcinoma (asterisk) in LP of MPAKT/Hi-MYC; stromal inflammation in MPAKT/Hi-Myc (arrowheads)
(H&E). Scale-bars: 50 mm.
doi:10.1371/journal.pone.0017449.g003
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Discussion
PI3K-pathway upregulation in primary and metastatic prostate
cancers provides the rationale for clinical evaluation of PI3K-
pathway inhibitors (including rapalogs). Here we demonstrate a
statistically significant co-occurrence of MYC amplification and
PI3K-pathway disruption in 194 human prostate tumors,
including 37 metastatic tumors. To investigate the potential
functional interaction between the MYC and PI3K-pathways in
the prostate, we first generated a PTENpc2/2/Hi-MYC bigenic
mouse that confirmed a prior model of cooperativity between
these two pathways [24]. Next, to further investigate the role of
PI3K downstream mediators in the interaction with MYC, we
crossbred previously characterized mice expressing activated
human AKT1 (MPAKT model) [14,29] and human MYC (Hi-
MYC model) [28]. In the resultant MPAKT/Hi-MYC model,
AKT1 and MYC are expressed together in the prostate,
recapitulating the co-incidence of the genetic lesions in human
prostate tumor samples.
The prostate glands of MPAKT/Hi-MYC mice are character-
ized by significant stromal reaction and infiltration of B- and T-
lymphocytes, as well as macrophages early in development of
mPIN and persisting throughout tumorigenesis. This inflammato-
ry response is of particular interest because of possible roles for the
immune system in tumor growth regulation. In the prostate,
inflammation is commonly observed in cancer precursor lesions
[34,38]. In addition, recent work has implicated infiltrating TH17
and/or Treg (FoxP3
+) T-cells in development or progression of
human prostate cancer [39]. Cytokines can confer survival to
tumor cells in xenografts derived from the Hi-MYC model,
facilitating prostate cancer progression [40]. Since it remains
unclear to what extent the inflammatory cells in human samples
play an active versus bystander role in cancer progression or
suppression, the MPAKT/Hi-MYC model may help address this
question. Indeed, genetically engineered mouse models of other
tumor types (breast, pancreatic islet cells, etc) have firmly
established both tumor-promoting and -suppressive actions for
distinct subsets of inflammatory cells [41].
Due to growing interest in evaluating PI3K-pathway inhibitors in
prostate cancer patients, we explored the activity of the rapamycin
analog RAD001 in the MPAKT/Hi-MYC model. In contrast to
the exquisite sensitivity of young MPAKT mice to this compound
Figure 5. The MPAKT/Hi-MYC phenotype is characterized by stromal inflammation. IHC of VP from mice aged 5–9 weeks, using antibodies
to differentiate macrophages (Mac-2), B-lymphocytes (B-220) or T-lymphocytes (CD3). Note periglandular stromal infiltration (arrows) in areas of mPIN,
unique to MPAKT/Hi-MYC (right panels) as compared to MPAKT or Hi-MYC. A few macrophages (upper panels) and T-lymphocytes (lower panels) are
present within glandular epithelium in mPIN from MPAKT and Hi-MYC (arrowheads). Scale-bars: 50 mm.
doi:10.1371/journal.pone.0017449.g005
Cooperation of MYC & AKT in Prostate Tumorigenesis
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17449
Figure 6. Dependence of the MPAKT phenotype on mTOR is abrogated by MYC expression, and attenuated with age. Prostates from
mice aged 7 weeks, treated for 2 weeks with either vehicle or 10 mg/kg RAD001. H&E panels: RAD001 treatment fully reverts the mPIN phenotype in
VP of 7-week-old MPAKT (n = 4–5/treatment group) - note reversion of nuclear atypia and re-polarization of basal nuclei. RAD001 treatment did not
revert LP lesions in Hi-MYC (n = 6/treatment group) and in MPAKT/Hi-MYC (n = 5–6/treatment group) (H&E). IHC panels: Patchy pAKT expression
remains detectable in reverted lesions of MPAKT mice, and in MPAKT/Hi-MYC, despite RAD001 treatment (see Fig. 3B for pAKT staining in vehicle-
treated mice). pS6 is strongly expressed in areas of mPIN in VP of vehicle-treated MPAKT and reduced by RAD001 treatment. pS6 staining in LP of
vehicle-treated Hi-MYC and MPAKT/Hi-MYC is patchy in mPIN. RAD001 treatment lowers but does not eliminate pS6 staining in Hi-MYC and MPAKT/
Hi-MYC. Scale-bars: 50 mm (black), 100 mm (red).
doi:10.1371/journal.pone.0017449.g006
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Figure 7. Dependence of the MPAKT phenotype on mTOR is abrogated by MYC expression, and attenuated with age. Prostates from
mice aged 32–33 weeks, treated for 2 weeks with either vehicle or 10 mg/kg RAD001. RAD001 treatment only variably reverts mPIN phenotype in VP
of 32–33-week-old MPAKT (H&E: upper panels: low-magnification, lower panels: high-magnification). mPIN lesions are preserved in vehicle-treated and
RAD001-resistant examples (diffuse in H&E, patchy in pS6 representative images (arrows). pS6 is strongly expressed in areas of mPIN in VP of vehicle-
treated MPAKT, and reduced by RAD001-treatment. (n = 6–7/treatment group; only 2 of 7 RAD001-treated mice responded). Scale-bars: 200 mm
(balck), 100 mm (red).
doi:10.1371/journal.pone.0017449.g007
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[14], MPAKT/Hi-MYC as well as older MPAKT mice were
completely or partially resistant, respectively. The mechanism of
resistance remains to be determined but we can likely exclude
pharmacologic explanations such as incomplete target inhibition.
Because recent evidence suggests perturbations in levels of the
eukaryotic elongation factor 4E (eIF-4E) or its inhibitor 4EBP1, a
translational regulator acting downstream of AKT and mTOR,
could mediate resistance [42] [43] [23], we considered this as a
potential mechanism for RAD001-resistance in the MPAKT/Hi-
MYC mice. However, bioinformatic mining of published tran-
scriptome data [28,29] revealed no significant changes in levels of
4EBP1 or eIF-4E in prostate tissues from Hi-MYC or MPAKT
mice. Furthermore, phosphorylation of 4EBP1 was unimpaired by
mTOR inhibition in these mice (but rather increased, possibly due to
feedback activation of the MEK/ERK-pathway [44]). Thus 4EBP1
is not a predictor of response to rapalog therapy in these mice.
Rapalogs, which selectively inhibit the TORC1 complex, can
paradoxically activate AKT through loss of S6 kinase-mediated
Figure 8. RAD001 increases p4EBP1 expression across genotypes, and decreases TUNEL in MPAKT/Hi-MYC and Hi-MYC tumors.
Prostates from mice aged 7-weeks, treated with either vehicle or 10 mg/kg RAD001. Upper panels, lower left panel: IHC of VP from 7-week-old mice.
14 d RAD001 treatment did not block p4EBP1 expression in prostates of any genotype (n = 4–6/treatment group, /genotype). Scale-bars: 100 mm.
Lower right panel: Cropped immunoblots after SDS-PAGE gel electrophoresis of protein lysates from VP of 7-week-old mice treated 2 d with vehicle or
RAD001 (full-length blots in Fig. S9). RAD001 did not lower (instead increased) p4EBP1 expression, despite successful inhibition of mTORC1, indicated
by decreased expression of downstream target pS6 and feedback upregulation of pGSK3b levels.
doi:10.1371/journal.pone.0017449.g008
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negative feedback at the level of PI3K [17]. While RAD001
resistance could be theoretically mediated through AKT activation
that results from TORC1 blockade, it is difficult to envision why
this would occur selectively in the MPAKT/Hi-MYC mice and
not in the young MPAKT mice, which are RAD001-sensitive.
Indeed, our analysis of phospho-AKT levels in RAD001 treated
animals revealed similar effects in both strains. Interestingly, the
rapamycin-resistant PrEC cells expressing activated PI3K and
MYC were sensitive to the dual PI3K/mTOR inhibitor BEZ235
[23], raising the possibility that reduced AKT activity is critical for
response.
Another potential mechanism for rapalog-resistance may be the
documented mitigation of cellular senescence upon mTOR
inhibition in tumors with activated senescence programs [45].
Figure 9. RAD001 increases p4EBP1 expression across genotypes, and decreases TUNEL in MPAKT/Hi-MYC and Hi-MYC tumors.
Prostates from mice aged 31–33 weeks, treated with either vehicle or 10 mg/kg RAD001. Representative TUNEL and Ki67 IHC-staining of prostate
tumors from 31–33week-old Hi-MYC and MPAKT/Hi-MYC. 14 d RAD001 treatment reduces TUNEL-staining, indicative of reduced apoptosis, but has
minimal effect on the Ki67 proliferative-marker. Images representative of all Hi-MYC (4/4 vehicle-treated, 5/5 RAD001-treated) and MPAKT/Hi-MYC (5/
5 vehicle-treated, 5/5 RAD001-treated) examined. Scale-bars: 100 mm.
doi:10.1371/journal.pone.0017449.g009
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We observed no consistent changes in expression of the
senescence-marker p27 by immunohistochemistry in MPAKT/
Hi-MYC and Hi-MYC prostates following RAD001 treatment
(not shown); however, we did observe a reduction in TUNEL
staining in RAD001-treated tumors. The mechanism of this pro-
survival effect of RAD001 treatment in the context of MYC
expression could be mediated through relief of mTOR-mediated
feedback (eg AKT activation) or other mechanisms requiring
further study.
Rapalogs have been explored in pilot studies in prostate cancer,
and PI3K and mTORC1/2 kinase inhibitors are now in early-
stage clinical trials across tumor types. In this context, our
demonstration that MYC overexpression can convert AKT-
activated mouse prostate tumors from rapalog-sensitive to
rapalog-resistant has implications for clinical studies of PI3K-
pathway inhibitors in men whose prostate cancers also harbor
increased AKT signaling. As is clear with other tumor types such
as glioblastoma and breast cancer, secondary genetic alterations
such as PTEN loss can mitigate the response to EGFR or HER2
inhibitors [46,47]. In light of the relatively disappointing single
agent activity of rapalogs in prostate cancer, it may be critical to
assess the MYC status of prostate tumors (among several other
markers) to guide the interpretation of response data in patients
undergoing PI3K inhibitor therapy.
Supporting Information
Figure S1 MYC amplification co-occurs with AKT
pathway activation in human prostate tumor samples.
Contingency tables for co-occurrence of MYC and PI3K-pathway
copy-number alterations (defined by aCGH) from (A) 157 primary
and 37 metastatic prostate tumor samples (n = 194 total), or from
(B, C) 37 metastatic samples alone. The tables indicate in red the
proportion of tumors with PIK3CA amplification or general PI3K
pathway gain, that also exhibit MYC amplification. (A), (B) The
association between multi-copy MYC amplification and single- or
multi-copy PI3K-pathway alterations is shown. (C) The associa-
tion between single- or multi-copy MYC gain and PI3K pathway
alterations is shown. The statistical significance of each association
is reported as a P-value determined by 2-tailed Fisher’s exact test.
(TIF)
Figure S2 MYC amplification co-occurs with AKT
pathway activation in human prostate tumor samples.
Graphic representation of contingency tables (Fig. 1, Fig. S1) for
co-occurrence of MYC and PI3K pathway copy number
alterations (as defined by aCGH in Methods) from (A) 157
primary and 37 metastatic prostate tumor samples (n = 194 total),
or from (B) 37 metastatic samples alone. The graphs indicate the
proportion of tumors with PIK3CA amplification or general PI3K
pathway gain, that also exhibit MYC amplification. The statistical
significance of each association is reported as a P-value determined
by 2-tailed Fisher’s exact test.
(TIF)
Figure S3 The AKT and MYC transgenes are expressed
in prostates of bigenic MPAKT/Hi-MYC mice, albeit at
lower levels than in the single transgenic mice. (A)
Immunohistochemistry using antibodies for pAKT (Ser473) and
MYC on ventral prostates from mice aged 30–33 weeks. Note the
high levels of pAKT membrane staining associated with regions of
mPIN in MPAKT/Hi-MYC mice. pAKT staining is absent in Hi-
MYC mice. Nuclear MYC staining is evident in Hi-MYC and
MPAKT/Hi-MYC, but absent in MPAKT mice. Scale-bars:
50 mm (black), 30 mm (red). (B) qRT-PCR analysis of the myr-HA-
AKT1 and MYC transgenes in prostates from 7 week-old MPAKT,
MPAKT/Hi-MYC and Hi-MYC mice (normalized to actin
mRNA, mean 6 SD, n= 6 prostates per genotype, run in
triplicate). P , 0.01 (determined by two-way ANOVA with
Bonferroni post-test) for Tg-AKT expression in MPAKT/Hi-
MYC vs MPAKT.
(TIF)
Figure S4 pAKT is expressed in cells near areas of
invasion in MPAKT/Hi-MYC mice. Invasive area in lateral
prostate of MPAKT/Hi-MYC mouse aged 21 weeks (upper
panels: hematoxylin & eosin). Lower panels: Immunohistochem-
istry using an antibody for pAKT (Ser473) indicates lower but
detectable pAKT expression in tumor cells compared to PIN
lesions. Scale bars: 200 mm (black), 100 mm (red).
(TIF)
Figure S5 Prostate epithelial cells display a higher
degree of nuclear atypia in PIN lesions from MPAKT/
Hi-MYC mice than from Hi-MYC mice. mPIN lesions in 8-
week-old lateral prostates from Hi-MYC and MPAKT/Hi-MYC
mice, indicating a greater degree of nuclear atypia in the
MPAKT/Hi-MYC cells with larger nuclei and more open
chromatin (H&E). Scale bars: 20 mm.
(TIF)
Figure S6 TheMPAKT/Hi-MYC ventral prostate displays
areas of stromal remodeling characteristic of microinva-
sive foci. Immunohistochemistry for smooth muscle actin and
collagen IV providing additional examples (as in Fig. 3C) of disrupted
and absent smooth muscle stroma and collagen IV surrounding
glands affected by mPIN in the MPAKT/Hi-MYC prostate (middle
and right columns). Note (left column), an example of minimally
attenuated smooth muscle sheath and collagen IV around a gland
with no evidence of microinvasion. Scale bars: 100 mm.
(TIF)
Figure S7 The MPAKT/Hi-MYC phenotype is charac-
terized by an increase in cell proliferation and apoptosis
compared to MPAKT mice, and the pro-apoptotic effects
of MYC are not rescued by AKT expression. Mouse
prostates from animals aged 5–9 weeks were stained with TUNEL
or antibody to Ki67. Results were quantified as the mean
percentage (6 SD) of positive cells, counting at least 300 cells
from representative areas (ventral prostate for most mice, and
mPIN lesions where present) from each of 9 mice per transgenic
genotype and 4 wild-type mice. P , 0.05 (determined by an
untailed t-test with two-tail p-value) for MPAKT/Hi-MYC vs
MPAKT, MPAKT/Hi-MYC vs WT, Hi-MYC vs MPAKT, Hi-
MYC vs WT.
(TIF)
Figure S8 mPIN lesions of older MPAKT mouse pros-
tates are variably resistant to RAD001. Additional examples
(as in Figure 7) showing that 14d RAD001 treatment only variably
reverts the mPIN phenotype in ventral prostates of 32–33 week-
old MPAKT mice (H&E). Note that mPIN lesions are preserved in
the RAD001-resistant examples, whereas the RAD001-sensitive
MPAKT example shows normal glands similar to that of a vehicle-
treated wild-type mouse. Note also that even in hyperplastic areas
of the wild-type glands, there is no nuclear atypia or cellular
hypertrophy (6–7 mice per treatment group; only 2 of 7 RAD001-
treated MPAKT mice responded). Scale bars: 200 mm (black),
100 mm (red).
(TIF)
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Figure S9 Uncropped immunoblots. Immunoblots from
which portions were cropped for display in Figure 8. Immunoblots
were prepared from 3 separate gels with matched loading of
identical samples, after SDS-PAGE electrophoresis of lysates from
ventral prostates of 7-week-old mice treated for 2 days with vehicle
or RAD001. PVDF membranes were cut horizontally prior to
probing with primary antibodies for p4EBP1 (Ser65), p4EBP1
(Thr37/46), total 4EBP1, pGSK3b (Ser9), pS6 (Ser240/244), and
b-actin to control for protein loading. RAD001 did not lower (but
instead increased) p4EBP1 expression, despite successful inhibition
of mTORC1 as indicated by decreased expression of downstream
target pS6 and feedback upregulation of pGSK3b levels.
(TIF)
Figure S10 Tumors in prostates of RAD001-treated Hi-
MYC and MPAKT/Hi-MYC mice display lower levels of
apoptosis and similar levels of proliferation compared
with vehicle-treated mice. Lower magnification views of
images displayed in Figure 9. Representative TUNEL and
immunohistochemical staining using an antibody for Ki67, of
prostate tumors from Hi-MYC and MPAKT/Hi-MYC mice aged
31–33 weeks. 14d RAD001 treatment reduces TUNEL staining in
tumors, indicative of reduced apoptosis, but has minimal effect on
the Ki67 proliferative marker. Images are representative of all
HiMYC mice (4/4 vehicle-treated, 5/5 RAD001-treated) and
MPAKT/Hi-MYC mice (5/5 vehicle-treated, 5/5 RAD001-
treated) examined. Scale bars: 200 mm (black), 500 mm (red).
(TIF)
Table S1 Primary copy number alternation data from
array CGH analysis.
(DOC)
Text S1 Supplemental Materials and Methods.
(PDF)
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